摘要:
A series of 2,3-diaminopyridine bradykinin B-1 antagonists was modified to mitigate the potential for bioactivation. Removal of the 3-amino group and incorporation of basic 5-piperazinyl carboxamides at the pyridine 5-position provided compounds with high affinity for the human B-1 receptor. (C) 2006 Elsevier Ltd. All rights reserved.